Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market, By Type (Afatinib, Trastuzumab, Olmesartan Medoxomil, Valsartan, Irbesartan, Telmisartan, Losartan, Eprosartan, Candesartan Cilexetil, Allisartan Isoproxil), Application (Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC, Left Ventricular Hypertrophy, Congestive Heart Failure, Atherosclerosis, High Blood Pressure, Others), Dosage (Tablet, Others), Route of Administration (Oral, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Analysis and Size
Rise in the prevalence of disorders such as hypertension, congestive heart failure and atherosclerosis, growing healthcare expenditure, increase use of the product in the treatment, supportive strategies and growing government funding are the factors that will expand the global non-peptide drugs of angiotensin II receptor antagonist market.
Data Bridge Market Research analyses that the global non-peptide drugs of angiotensin II receptor antagonist market, which was USD 177,430.32million in 2022, is expected to reach USD 325,986.34 million by 2030, and is expected to undergo a CAGR of 9.10% during the forecast period 2023-2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Afatinib, Trastuzumab, Olmesartan Medoxomil, Valsartan, Irbesartan, Telmisartan, Losartan, Eprosartan, Candesartan Cilexetil, Allisartan Isoproxil), Application (Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC, Left Ventricular Hypertrophy, Congestive Heart Failure, Atherosclerosis, High Blood Pressure, Others), Dosage (Tablet, Others), Route of Administration (Oral, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Novartis (Switzerland), Daiichi Sankyo (Japan), Takeda Pharmaceutical Company (Japan), Boehringer Ingelheim (Germany), AstraZeneca (U.K.), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), GlaxoSmithKline (GSK) (United Kingdom), Bayer (Germany), Mylan (United States), Sun Pharmaceutical Industries (India), Torrent Pharmaceuticals (India), Zydus Cadila (India), Cipla (India), Glenmark Pharmaceuticals (India), Mitsubishi Tanabe Pharma (Japan), Ipca Laboratories (India) |
|
Market Opportunities |
|
Market Definition
Non-peptide drugs of Angiotensin II receptor antagonists (also known as Angiotensin II receptor blockers or ARBs) are a class of medications used to treat conditions like hypertension (high blood pressure) and certain cardiovascular conditions. They work by blocking the action of angiotensin II, a hormone that narrows blood vessels and raises blood pressure. By doing so, ARBs help relax blood vessels, lower blood pressure, and reduce the workload on the heart.
Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Dynamics
Drivers
- High Prevalence of Hypertension
Hypertension, or high blood pressure, is a widespread health issue globally. It affects a large portion of the population and is a significant risk factor for cardiovascular diseases. ARBs are commonly prescribed for hypertension management, making them a fundamental component of the market.
- Aging Population
As the global population ages, the prevalence of chronic conditions like hypertension and heart disease tends to increase. Older individuals often require ongoing treatment, contributing to the sustained demand for ARBs
- Clinical Research and Innovation
Ongoing research into ARBs and related pharmaceuticals continues to uncover new applications and therapeutic benefits. This research-driven innovation keeps the market dynamic and encourages the development of new ARB formulations and combination therapies.
Opportunities
- Rising Awareness
Increasing awareness of the importance of managing hypertension and cardiovascular health among patients and healthcare providers has led to greater diagnosis and treatment rates. This, in turn, boosts the ARB market.
- Rising Government Initiatives
Government initiatives to control and manage non-communicable diseases, including hypertension, play a role in boosting the ARB market. Public health campaigns and policies that encourage regular blood pressure monitoring and treatment contribute to demand
Restraints/Challenges
- Competition from Generics
The entry of generic ARBs into the market, once patents expire, can reduce the market share and profitability of branded ARB medications. This competition often results in price erosion and can hinder revenue growth.
- Stringent Regulatory Approvals
The pharmaceutical industry is heavily regulated, with rigorous clinical trial requirements and approval processes. Obtaining regulatory approvals for new ARB drugs or indications can be time-consuming and costly.
This global non-peptide drugs of angiotensin II receptor antagonist market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global non-peptide drugs of angiotensin II receptor antagonist market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October 2020, Glenmark Pharmaceuticals received final approval from the FDA for its abbreviated new drug application (ANDA) for telmisartan tablets, used for the treatment of hypertension
- In September 2020, Aurobindo Pharma received final approval from the FDA for its ANDA for candesartan cilexetil tablets, used for the treatment of hypertension
Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Scope
Global non-peptide drugs of angiotensin II receptor antagonist market are segmented on the basis of type, application, dosage, route of administration and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Afatinib
- Trastuzumab
- Olmesartan
- Medoxomil
- Valsartan
- Irbesartan
- Telmisartan
- Losartan
- Eprosartan
- Candesartan Cilexetil
- Allisartan Isoproxil
Application
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Left Ventricular Hypertrophy
- Congestive Heart Failure
- Atherosclerosis
- High Blood Pressure
- Others
Dosage
- Tablet
- Others
Route of Administration
- Oral
- Other
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Analysis/Insights
The global non-peptide drugs of angiotensin II receptor antagonist market are analysed and market size insights and trends are provided by country, type, application, dosage, route of administration and distribution channel as referenced above.
The countries covered in the global non-peptide drugs of angiotensin II receptor antagonist market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global non-peptide drugs of angiotensin II receptor antagonist market because of the strong base of healthcare facilities, strong presence of major players in the market, rising demand of the non-peptide drugs of angiotensin II receptor antagonist products and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Analysis
Global non-peptide drugs of angiotensin II receptor antagonist market competitive landscape provide details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global non-peptide drugs of angiotensin II receptor antagonist market.
Some of the major players operating in the global non-peptide drugs of angiotensin II receptor antagonist market are:
- Novartis (Switzerland)
- Daiichi Sankyo (Japan)
- Takeda Pharmaceutical Company (Japan)
- Boehringer Ingelheim (Germany)
- AstraZeneca (U.K.)
- Pfizer (U.S.)
- Sanofi (France)
- Merck & Co. (U.S.)
- Eli Lilly and Company (U.S.)
- Bristol-Myers Squibb (U.S.)
- GlaxoSmithKline (GSK) (United Kingdom)
- Bayer (Germany)
- Mylan (United States)
- Sun Pharmaceutical Industries (India)
- Torrent Pharmaceuticals (India)
- Zydus Cadila (India)
- Cipla (India)
- Glenmark Pharmaceuticals (India)
- Mitsubishi Tanabe Pharma (Japan)
- Ipca Laboratories (India)
SKU-
